Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A T7 RNAP regulatory toolbox for cell-free network engineering and biosensing applications.

Nature communications·2026
Same author

PURE makes PURE: reconstitution of the PURE cell-free system from self-synthesized proteins.

Nature communications·2026
Same author

Integrated Microfluidic Platform for High-Throughput Generation of Intestinal Organoids in Hydrogel Droplets.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Microfluidics meets cell-free systems: from molecular engineering to synthetic cells.

Current opinion in biotechnology·2025
Same author

Integrating microfluidic automation into thermoplastic devices for analysis of small volumes of blood.

Biosensors & bioelectronics·2025
Same author

Evolving infectious disease dynamics shape school-based intervention effectiveness.

Nature communications·2025

Related Experiment Video

Updated: May 4, 2026

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

2.0K

A 1024-sample serum analyzer chip for cancer diagnostics.

Jose L Garcia-Cordero1, Sebastian J Maerkl

  • 1Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. Sebastian.maerkl@epfl.ch.

Lab on a Chip
|December 19, 2013
PubMed
Summary

This study introduces a novel microarray and microfluidic platform for high-throughput protein biomarker quantification. The technology enables rapid, low-cost detection of key biomarkers like PSA, significantly impacting disease diagnosis and management.

More Related Videos

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

985
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

10.5K

Related Experiment Videos

Last Updated: May 4, 2026

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

2.0K
Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

985
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

10.5K

Area of Science:

  • Biomedical Engineering
  • Biotechnology
  • Analytical Chemistry

Background:

  • Accurate protein biomarker quantification is crucial for disease diagnosis and management.
  • Existing methods like ELISA can be costly and time-consuming for high-throughput screening.
  • There is a need for integrated, cost-effective platforms for large-scale biomarker analysis.

Purpose of the Study:

  • To develop and validate a novel platform combining microarrays and microfluidics for protein biomarker detection.
  • To assess the platform's performance in quantifying prostate-specific antigen (PSA), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6).
  • To evaluate the platform's cost-effectiveness and throughput compared to conventional methods.

Main Methods:

  • Development of a microarray-based platform integrated with microfluidic technology.
  • Utilized a surface fluorescence sandwich immunoassay for protein detection.
  • Measured four protein biomarkers (PSA, TNF-α, IL-1β, IL-6) in 1024 serum samples (4096 assays per device).
  • Validated the platform using 20 clinical serum samples (10 prostate cancer patients, 10 controls).
  • Compared results with conventional Enzyme-Linked Immunosorbent Assay (ELISA).

Main Results:

  • Achieved a limit of detection of approximately 1 pM for most measured proteins.
  • Demonstrated good correlation between the novel platform and conventional ELISA.
  • Reduced reagent costs by 4 orders of magnitude compared to ELISA.
  • Increased throughput by 2 orders of magnitude compared to ELISA.
  • Successfully quantified biomarkers in over one thousand serum samples.

Conclusions:

  • The integrated microarray and microfluidic platform offers a low-cost, high-throughput solution for protein biomarker quantification.
  • This technology has the potential to significantly advance disease diagnosis and patient management.
  • The platform provides a rapid and efficient alternative to traditional methods for large-scale biomarker analysis.